{
  "id": "6020b5681cb411341a000088",
  "type": "factoid",
  "question": "Which mutation is targeted by Tepotinib?",
  "ideal_answer": "MET Exon 14 Skipping Mutation is targeted by Tepotinib that is used for patients with non-small-cell lung cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34037224",
    "http://www.ncbi.nlm.nih.gov/pubmed/32716573",
    "http://www.ncbi.nlm.nih.gov/pubmed/33818908",
    "http://www.ncbi.nlm.nih.gov/pubmed/32702795",
    "http://www.ncbi.nlm.nih.gov/pubmed/32469185",
    "http://www.ncbi.nlm.nih.gov/pubmed/33335011",
    "http://www.ncbi.nlm.nih.gov/pubmed/28024693",
    "http://www.ncbi.nlm.nih.gov/pubmed/33533182",
    "http://www.ncbi.nlm.nih.gov/pubmed/32306194",
    "http://www.ncbi.nlm.nih.gov/pubmed/34590003",
    "http://www.ncbi.nlm.nih.gov/pubmed/34295201",
    "http://www.ncbi.nlm.nih.gov/pubmed/33851690",
    "http://www.ncbi.nlm.nih.gov/pubmed/33305187",
    "http://www.ncbi.nlm.nih.gov/pubmed/34295669",
    "http://www.ncbi.nlm.nih.gov/pubmed/33387444"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306194",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "If type I MET inhibitors (crizotinib, capmatinib, tepotinib, savolitinib) drug resistance is developed, type II MET inhibitors (cabozantinib, glesatinib, merestinib) can be considered.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306194",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Drugs targeting MET 14 exon skipping mutation bring new hope to patients. MET inhibitors that are currently on the market or are about to be marketed include: crizotinib, cabozantinib, savolitinib and tepotinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32702795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "At least five MET-targeted TKIs, including crizotinib, cabozantinib, capmatinib, tepotinib, and glesatinib, are being investigated clinically for patients with MET exon 14 altered-NSCLC. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28024693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tepotinib hydrochloride is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33851690",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "hibitors for MET exon 14 skipping mutation such as capmatinib and tepotinib have elucidated their effectiveness. Only a few reports have suggested their efficacy ag",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ET exon 14 skipping mutation and poor performance status salvaged by marked leptomeningeal metastases response to tepotinib. We further provide measures of plasma/cerebrospinal fluid concentrations of t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tepotinib is a key drug for cancer patients with mesenchymal-epithelial transition receptor tyrosine kinase proto-oncogene (MET) exon 14 skipping mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33387444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herein, we report a case of a patient with metastatic lung adenocarcinoma harboring a MET exon 14 splice site mutation who has had prolonged disease control by a second-generation MET-TKI tepotinib. A 66-yr-old man was diagn",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33335011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, in METex14-mutated NSCLC, multitarget tyrosine kinase inhibitors (TKIs), such as crizotinib and cabozantinib, as well as MET-selective TKIs, such as tepotinib and capmatinib, have demonstrated durable responses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32716573",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Ex",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "(NSCLC). The MET inhibitor tepotinib has demonstrated clinical efficacy in patients with MET exon 14 skipp",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34037224",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ification (~14%). In 2020, the approval of two MET-tyrosine kinase inhibitors (TKIs), capmatinib and tepotinib, for NSCLCs carrying MET\u2206ex14 dawned a new era for ME",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34295201",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations (e.g., capmatinib, tepotinib) are a new and important therapeutic option for the treatment of non-small cell lung cancer (NSCLC) patients harbouring c-MET alterations. Seve",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34295669",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ", in METex14-mutated NSCLC, multitarget tyrosine kinase inhibitors (TKIs), such as crizotinib and cabozantinib, as well as MET-selective TKIs, such as tepotinib and capmatinib, have demonstrated durable responses. In this study",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32716573",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tudies reported that NSCLC patients harboring a METex14del responded well to MET-tyrosine kinase inhibitors (TKIs), including tepotinib. Tepotinib ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33533182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rgeted TKIs, including crizotinib, cabozantinib, capmatinib, tepotinib, and glesatinib, are being investigated clinically for patients with MET exon 14 altered-NSCLC. A further two compounds ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28024693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tepotinib is a key drug for cancer patients with mesenchymal-epithelial transition receptor tyrosine kinase proto-oncogene (MET) exon 14 skipping mutation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33387444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". Several tyrosine kinase inhibitors for MET exon 14 skipping mutation such as capmatinib and tepotinib have elucidated their effect",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tepotinib at this dose has obtained regulatory approval for the treatment of patients with non-small cell lung cancer harboring MET exon 14 skipping.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33818908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33387444",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skipping mutations identifies other receptor tyrosine kinases (RTKs) that co-exist in cells prior to tepotinib exposure and become more prominent upon tepotinib resistance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305187",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "MET Exon 14 Skipping Mutation"
}